| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Protease | 73 | 2023 | 119 | 15.720 |
Why?
|
| Drug Resistance, Viral | 61 | 2025 | 156 | 13.130 |
Why?
|
| HIV Protease Inhibitors | 56 | 2023 | 105 | 10.930 |
Why?
|
| Antiviral Agents | 33 | 2025 | 329 | 9.220 |
Why?
|
| HIV-1 | 61 | 2025 | 725 | 8.810 |
Why?
|
| Viral Nonstructural Proteins | 23 | 2022 | 95 | 7.170 |
Why?
|
| Protease Inhibitors | 22 | 2025 | 106 | 6.420 |
Why?
|
| Catalytic Domain | 33 | 2026 | 205 | 5.030 |
Why?
|
| Hepacivirus | 18 | 2022 | 140 | 4.610 |
Why?
|
| Models, Molecular | 86 | 2026 | 1160 | 4.410 |
Why?
|
| Sulfonamides | 19 | 2022 | 131 | 4.320 |
Why?
|
| Crystallography, X-Ray | 65 | 2025 | 436 | 4.240 |
Why?
|
| Molecular Dynamics Simulation | 24 | 2024 | 123 | 4.220 |
Why?
|
| Mutation | 65 | 2026 | 2633 | 3.960 |
Why?
|
| Cytidine Deaminase | 13 | 2025 | 86 | 3.890 |
Why?
|
| Drug Design | 20 | 2022 | 138 | 3.770 |
Why?
|
| Protein Binding | 51 | 2026 | 1619 | 3.500 |
Why?
|
| Protein Conformation | 51 | 2025 | 785 | 3.290 |
Why?
|
| DNA, Single-Stranded | 10 | 2022 | 107 | 3.120 |
Why?
|
| Darunavir | 16 | 2023 | 30 | 3.090 |
Why?
|
| Quinoxalines | 8 | 2022 | 37 | 2.970 |
Why?
|
| Substrate Specificity | 34 | 2024 | 340 | 2.570 |
Why?
|
| Viral Proteins | 10 | 2025 | 266 | 2.540 |
Why?
|
| Hepatitis C | 8 | 2021 | 152 | 2.390 |
Why?
|
| Serine Endopeptidases | 16 | 2022 | 121 | 2.300 |
Why?
|
| Leucine | 9 | 2025 | 67 | 2.150 |
Why?
|
| Enzyme Inhibitors | 9 | 2025 | 373 | 2.140 |
Why?
|
| gag Gene Products, Human Immunodeficiency Virus | 10 | 2020 | 38 | 2.130 |
Why?
|
| Machine Learning | 5 | 2021 | 184 | 1.980 |
Why?
|
| Enterovirus D, Human | 3 | 2025 | 11 | 1.940 |
Why?
|
| Cysteine Endopeptidases | 5 | 2025 | 97 | 1.940 |
Why?
|
| Peptide Hydrolases | 9 | 2025 | 80 | 1.920 |
Why?
|
| Lactams, Macrocyclic | 6 | 2022 | 31 | 1.850 |
Why?
|
| Structure-Activity Relationship | 29 | 2023 | 374 | 1.840 |
Why?
|
| Proline | 6 | 2025 | 49 | 1.840 |
Why?
|
| Cyclopropanes | 6 | 2022 | 54 | 1.830 |
Why?
|
| APOBEC Deaminases | 5 | 2025 | 10 | 1.830 |
Why?
|
| Binding Sites | 35 | 2025 | 914 | 1.810 |
Why?
|
| Humans | 166 | 2026 | 64270 | 1.630 |
Why?
|
| Drug Resistance | 6 | 2024 | 155 | 1.600 |
Why?
|
| Aminoisobutyric Acids | 3 | 2022 | 9 | 1.510 |
Why?
|
| Hydrogen Bonding | 20 | 2021 | 129 | 1.460 |
Why?
|
| Proteins | 9 | 2018 | 760 | 1.430 |
Why?
|
| Amino Acid Sequence | 26 | 2021 | 1597 | 1.410 |
Why?
|
| Carrier Proteins | 7 | 2025 | 709 | 1.410 |
Why?
|
| HIV Infections | 17 | 2024 | 976 | 1.410 |
Why?
|
| vif Gene Products, Human Immunodeficiency Virus | 5 | 2025 | 13 | 1.380 |
Why?
|
| Molecular Docking Simulation | 8 | 2023 | 80 | 1.330 |
Why?
|
| Drug Discovery | 6 | 2023 | 98 | 1.240 |
Why?
|
| Nucleoside-Triphosphatase | 13 | 2020 | 41 | 1.210 |
Why?
|
| Thermodynamics | 19 | 2016 | 199 | 1.200 |
Why?
|
| DEAD-box RNA Helicases | 13 | 2020 | 129 | 1.140 |
Why?
|
| Evolution, Molecular | 9 | 2019 | 324 | 1.100 |
Why?
|
| Hemagglutinin Glycoproteins, Influenza Virus | 8 | 2025 | 42 | 1.010 |
Why?
|
| Protein Structure, Tertiary | 14 | 2015 | 674 | 1.000 |
Why?
|
| Polyproteins | 4 | 2016 | 8 | 0.990 |
Why?
|
| Dengue Virus | 2 | 2017 | 99 | 0.980 |
Why?
|
| Mutation, Missense | 5 | 2019 | 185 | 0.970 |
Why?
|
| Serine Proteases | 4 | 2021 | 12 | 0.970 |
Why?
|
| Coronavirus, Feline | 1 | 2025 | 2 | 0.960 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 5 | 2019 | 113 | 0.940 |
Why?
|
| APOBEC-3G Deaminase | 10 | 2022 | 21 | 0.930 |
Why?
|
| Static Electricity | 9 | 2021 | 168 | 0.930 |
Why?
|
| Gene Editing | 3 | 2025 | 323 | 0.930 |
Why?
|
| Ligands | 10 | 2020 | 417 | 0.920 |
Why?
|
| CRISPR-Cas Systems | 3 | 2025 | 364 | 0.900 |
Why?
|
| DNA | 6 | 2021 | 844 | 0.900 |
Why?
|
| Cytosine | 1 | 2025 | 30 | 0.890 |
Why?
|
| Cytosine Deaminase | 2 | 2014 | 6 | 0.850 |
Why?
|
| Neuraminidase | 5 | 2022 | 43 | 0.830 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 7 | 2022 | 91 | 0.830 |
Why?
|
| Cytidine | 4 | 2025 | 15 | 0.830 |
Why?
|
| Ribonucleoproteins | 1 | 2025 | 116 | 0.830 |
Why?
|
| Drug Resistance, Multiple, Viral | 8 | 2018 | 14 | 0.830 |
Why?
|
| Communicable Diseases | 2 | 2022 | 91 | 0.820 |
Why?
|
| Anti-HIV Agents | 5 | 2019 | 156 | 0.820 |
Why?
|
| Amino Acid Substitution | 10 | 2019 | 239 | 0.810 |
Why?
|
| Flavivirus | 1 | 2022 | 8 | 0.780 |
Why?
|
| Nelfinavir | 4 | 2014 | 7 | 0.770 |
Why?
|
| RNA | 4 | 2021 | 429 | 0.770 |
Why?
|
| Alcohol Oxidoreductases | 6 | 2021 | 28 | 0.770 |
Why?
|
| Valine | 3 | 2021 | 33 | 0.770 |
Why?
|
| Influenza A virus | 4 | 2022 | 124 | 0.760 |
Why?
|
| Phenylalanine | 2 | 2021 | 26 | 0.750 |
Why?
|
| Zika Virus | 1 | 2022 | 36 | 0.750 |
Why?
|
| Aspartic Acid Endopeptidases | 2 | 2021 | 37 | 0.740 |
Why?
|
| Zika Virus Infection | 1 | 2022 | 37 | 0.740 |
Why?
|
| Pyrrolidinones | 1 | 2021 | 11 | 0.720 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 2021 | 23 | 0.710 |
Why?
|
| Isoxazoles | 1 | 2021 | 14 | 0.710 |
Why?
|
| Drug Resistance, Fungal | 1 | 2021 | 11 | 0.700 |
Why?
|
| Pneumocystis carinii | 1 | 2021 | 8 | 0.700 |
Why?
|
| Kinetics | 12 | 2018 | 766 | 0.700 |
Why?
|
| Pharmaceutical Preparations | 2 | 2021 | 123 | 0.700 |
Why?
|
| Antibodies, Neutralizing | 6 | 2026 | 214 | 0.690 |
Why?
|
| Human T-lymphotropic virus 1 | 1 | 2021 | 5 | 0.690 |
Why?
|
| Computer Simulation | 13 | 2017 | 482 | 0.680 |
Why?
|
| Lactams | 5 | 2025 | 24 | 0.670 |
Why?
|
| Water | 8 | 2019 | 314 | 0.660 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2018 | 202 | 0.650 |
Why?
|
| DNA-Binding Proteins | 8 | 2021 | 1195 | 0.640 |
Why?
|
| Peptides, Cyclic | 3 | 2017 | 24 | 0.640 |
Why?
|
| Serine Proteinase Inhibitors | 1 | 2020 | 10 | 0.640 |
Why?
|
| Molecular Structure | 13 | 2021 | 386 | 0.630 |
Why?
|
| Virus Diseases | 1 | 2021 | 123 | 0.630 |
Why?
|
| Drug Resistance, Microbial | 2 | 2018 | 48 | 0.620 |
Why?
|
| Carbamates | 7 | 2020 | 26 | 0.610 |
Why?
|
| Neoplasms | 2 | 2021 | 1393 | 0.610 |
Why?
|
| Gene Products, gag | 5 | 2006 | 67 | 0.590 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2018 | 35 | 0.580 |
Why?
|
| Antibodies, Viral | 6 | 2026 | 329 | 0.580 |
Why?
|
| Macrocyclic Compounds | 2 | 2021 | 12 | 0.580 |
Why?
|
| Molecular Sequence Data | 20 | 2011 | 1999 | 0.570 |
Why?
|
| Immunoglobulin A | 3 | 2026 | 98 | 0.560 |
Why?
|
| Oseltamivir | 5 | 2022 | 35 | 0.550 |
Why?
|
| Protein Structure, Secondary | 10 | 2018 | 260 | 0.540 |
Why?
|
| Aprotinin | 5 | 2017 | 11 | 0.530 |
Why?
|
| Benzimidazoles | 1 | 2017 | 56 | 0.530 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 7 | 2001 | 457 | 0.500 |
Why?
|
| Macromolecular Substances | 2 | 2015 | 160 | 0.490 |
Why?
|
| Genetic Variation | 3 | 2008 | 387 | 0.490 |
Why?
|
| Dengue | 1 | 2016 | 96 | 0.490 |
Why?
|
| Amides | 4 | 2020 | 56 | 0.480 |
Why?
|
| Leukemia, Myeloid | 9 | 2001 | 36 | 0.470 |
Why?
|
| Automation, Laboratory | 1 | 2015 | 9 | 0.460 |
Why?
|
| Genotype | 2 | 2016 | 668 | 0.460 |
Why?
|
| Animals | 31 | 2026 | 20955 | 0.450 |
Why?
|
| Influenza, Human | 6 | 2022 | 212 | 0.450 |
Why?
|
| Enterovirus Infections | 2 | 2025 | 12 | 0.450 |
Why?
|
| Cytarabine | 9 | 2001 | 38 | 0.440 |
Why?
|
| Isoquinolines | 1 | 2014 | 33 | 0.440 |
Why?
|
| Dipeptides | 4 | 2020 | 68 | 0.430 |
Why?
|
| Co-Repressor Proteins | 5 | 2021 | 22 | 0.430 |
Why?
|
| Single-Domain Antibodies | 2 | 2026 | 20 | 0.430 |
Why?
|
| Peptide Fragments | 6 | 2014 | 417 | 0.420 |
Why?
|
| Software | 3 | 2015 | 388 | 0.420 |
Why?
|
| Protein Engineering | 2 | 2026 | 85 | 0.420 |
Why?
|
| Peptides | 6 | 2015 | 590 | 0.420 |
Why?
|
| Multifunctional Enzymes | 1 | 2013 | 18 | 0.410 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 5 | 2014 | 342 | 0.410 |
Why?
|
| Protein Multimerization | 8 | 2026 | 182 | 0.410 |
Why?
|
| Data Collection | 1 | 2015 | 384 | 0.410 |
Why?
|
| Epitopes | 5 | 2022 | 292 | 0.390 |
Why?
|
| RNA Helicases | 1 | 2013 | 95 | 0.390 |
Why?
|
| HEK293 Cells | 8 | 2025 | 626 | 0.390 |
Why?
|
| Oligonucleotides | 2 | 2025 | 226 | 0.370 |
Why?
|
| Antineoplastic Agents | 7 | 2021 | 667 | 0.360 |
Why?
|
| DNA Helicases | 1 | 2013 | 192 | 0.360 |
Why?
|
| Research | 1 | 2013 | 196 | 0.360 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 6 | 2018 | 272 | 0.360 |
Why?
|
| Protein Structure, Quaternary | 7 | 2016 | 100 | 0.360 |
Why?
|
| Point Mutation | 5 | 2019 | 165 | 0.340 |
Why?
|
| Computational Biology | 7 | 2021 | 357 | 0.340 |
Why?
|
| Magnetic Resonance Spectroscopy | 7 | 2019 | 296 | 0.340 |
Why?
|
| Furans | 4 | 2020 | 33 | 0.330 |
Why?
|
| Nitriles | 3 | 2025 | 79 | 0.320 |
Why?
|
| Indoles | 2 | 2025 | 115 | 0.310 |
Why?
|
| Leukemia, Myeloid, Acute | 7 | 2012 | 192 | 0.310 |
Why?
|
| Virion | 4 | 2025 | 121 | 0.300 |
Why?
|
| Nerve Tissue Proteins | 3 | 2018 | 429 | 0.300 |
Why?
|
| Solvents | 6 | 2003 | 58 | 0.300 |
Why?
|
| Spike Glycoprotein, Coronavirus | 4 | 2026 | 116 | 0.290 |
Why?
|
| Oligopeptides | 5 | 2015 | 135 | 0.290 |
Why?
|
| Protein Folding | 5 | 2015 | 268 | 0.290 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2011 | 432 | 0.280 |
Why?
|
| Nucleocapsid Proteins | 2 | 2006 | 36 | 0.280 |
Why?
|
| Gene Products, vif | 1 | 2007 | 9 | 0.280 |
Why?
|
| Recombinant Fusion Proteins | 5 | 2026 | 495 | 0.270 |
Why?
|
| Models, Chemical | 5 | 2012 | 140 | 0.270 |
Why?
|
| Repressor Proteins | 3 | 2010 | 348 | 0.270 |
Why?
|
| Leukemia | 4 | 2017 | 60 | 0.270 |
Why?
|
| Methionine | 4 | 2019 | 57 | 0.270 |
Why?
|
| Thymidylate Synthase | 4 | 2009 | 6 | 0.260 |
Why?
|
| Proteomics | 2 | 2022 | 294 | 0.260 |
Why?
|
| Capsid | 2 | 2013 | 97 | 0.250 |
Why?
|
| Sequence Homology, Amino Acid | 4 | 2017 | 365 | 0.250 |
Why?
|
| Selection, Genetic | 3 | 2019 | 83 | 0.250 |
Why?
|
| Tryptophan | 1 | 2006 | 56 | 0.250 |
Why?
|
| Macaca mulatta | 2 | 2024 | 256 | 0.240 |
Why?
|
| Membrane Proteins | 2 | 2011 | 908 | 0.240 |
Why?
|
| Sequence Alignment | 4 | 2017 | 302 | 0.240 |
Why?
|
| Sulfonic Acids | 1 | 2025 | 11 | 0.240 |
Why?
|
| Aminohydrolases | 1 | 2025 | 4 | 0.230 |
Why?
|
| Cats | 1 | 2025 | 89 | 0.230 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2026 | 43 | 0.230 |
Why?
|
| Dimerization | 5 | 2015 | 146 | 0.230 |
Why?
|
| Calorimetry | 4 | 2012 | 40 | 0.230 |
Why?
|
| Mutagenesis, Site-Directed | 6 | 2016 | 248 | 0.220 |
Why?
|
| Crystallization | 5 | 2011 | 101 | 0.220 |
Why?
|
| Quantum Theory | 2 | 2003 | 8 | 0.220 |
Why?
|
| Inhibitory Concentration 50 | 3 | 2021 | 93 | 0.220 |
Why?
|
| N-Acetylneuraminic Acid | 1 | 2025 | 48 | 0.220 |
Why?
|
| Biocatalysis | 3 | 2019 | 49 | 0.220 |
Why?
|
| Receptors, Fc | 1 | 2024 | 24 | 0.220 |
Why?
|
| Deoxyribonucleotides | 1 | 2024 | 13 | 0.220 |
Why?
|
| Amino Acid Motifs | 4 | 2018 | 153 | 0.220 |
Why?
|
| Proteolysis | 4 | 2025 | 149 | 0.220 |
Why?
|
| Anemia, Sickle Cell | 1 | 2025 | 64 | 0.220 |
Why?
|
| RNA-Directed DNA Polymerase | 1 | 2024 | 40 | 0.210 |
Why?
|
| Mice | 9 | 2026 | 10994 | 0.210 |
Why?
|
| Receptors, CCR5 | 1 | 2024 | 59 | 0.210 |
Why?
|
| NADP | 2 | 2021 | 22 | 0.210 |
Why?
|
| Fetus | 1 | 2024 | 100 | 0.210 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 3 | 2001 | 46 | 0.210 |
Why?
|
| Cell Line | 12 | 2019 | 2057 | 0.210 |
Why?
|
| NAD | 3 | 2021 | 52 | 0.210 |
Why?
|
| Gene Products, pol | 1 | 2003 | 9 | 0.200 |
Why?
|
| Influenza Vaccines | 3 | 2021 | 101 | 0.200 |
Why?
|
| Orthomyxoviridae | 2 | 2021 | 26 | 0.200 |
Why?
|
| Electrochemistry | 1 | 2003 | 27 | 0.200 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2024 | 145 | 0.200 |
Why?
|
| Genome, Viral | 2 | 2015 | 140 | 0.200 |
Why?
|
| Chemistry Techniques, Analytical | 1 | 2003 | 3 | 0.200 |
Why?
|
| Deamination | 3 | 2019 | 11 | 0.200 |
Why?
|
| Tetrahydrofolate Dehydrogenase | 2 | 2021 | 22 | 0.200 |
Why?
|
| Amino Acids | 2 | 2018 | 148 | 0.190 |
Why?
|
| Zinc | 3 | 2020 | 93 | 0.190 |
Why?
|
| Molecular Targeted Therapy | 2 | 2021 | 129 | 0.190 |
Why?
|
| Protein Denaturation | 3 | 2019 | 67 | 0.190 |
Why?
|
| Halogenation | 1 | 2022 | 4 | 0.190 |
Why?
|
| Receptors, Somatotropin | 1 | 2002 | 3 | 0.190 |
Why?
|
| Fluorine | 1 | 2022 | 9 | 0.180 |
Why?
|
| Human Growth Hormone | 1 | 2002 | 19 | 0.180 |
Why?
|
| Escherichia coli | 5 | 2022 | 718 | 0.180 |
Why?
|
| Virus Replication | 6 | 2021 | 324 | 0.180 |
Why?
|
| Hepatitis C, Chronic | 1 | 2022 | 89 | 0.180 |
Why?
|
| Monte Carlo Method | 2 | 2020 | 90 | 0.180 |
Why?
|
| Dose-Response Relationship, Drug | 8 | 2019 | 869 | 0.180 |
Why?
|
| Antibody Affinity | 1 | 2021 | 19 | 0.180 |
Why?
|
| Skin Diseases, Infectious | 1 | 2001 | 12 | 0.180 |
Why?
|
| Cryoelectron Microscopy | 4 | 2025 | 207 | 0.180 |
Why?
|
| Signal Transduction | 3 | 2021 | 3068 | 0.180 |
Why?
|
| Bacterial Outer Membrane Proteins | 2 | 2016 | 123 | 0.170 |
Why?
|
| Antibodies, Monoclonal | 4 | 2024 | 870 | 0.170 |
Why?
|
| Herbicides | 1 | 2021 | 19 | 0.170 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2021 | 99 | 0.170 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2004 | 727 | 0.170 |
Why?
|
| Respiratory Tract Infections | 1 | 2001 | 90 | 0.170 |
Why?
|
| Monoamine Oxidase | 1 | 2020 | 8 | 0.170 |
Why?
|
| Dogs | 7 | 2019 | 332 | 0.170 |
Why?
|
| Pandemics | 2 | 2023 | 676 | 0.170 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2024 | 248 | 0.160 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2020 | 45 | 0.160 |
Why?
|
| Protein Domains | 2 | 2020 | 154 | 0.160 |
Why?
|
| Pesticides | 1 | 2021 | 56 | 0.160 |
Why?
|
| Remission Induction | 10 | 2012 | 147 | 0.160 |
Why?
|
| Crystallography | 5 | 2009 | 26 | 0.160 |
Why?
|
| Enzyme Activation | 3 | 2012 | 386 | 0.160 |
Why?
|
| Conserved Sequence | 3 | 2011 | 173 | 0.160 |
Why?
|
| Epistasis, Genetic | 1 | 2019 | 42 | 0.150 |
Why?
|
| Oxazolidinones | 2 | 2010 | 15 | 0.150 |
Why?
|
| Anti-Infective Agents | 1 | 2021 | 150 | 0.150 |
Why?
|
| Insulin-Secreting Cells | 1 | 2020 | 189 | 0.150 |
Why?
|
| Host-Pathogen Interactions | 1 | 2021 | 266 | 0.150 |
Why?
|
| Seminal Plasma Proteins | 1 | 2018 | 8 | 0.150 |
Why?
|
| Prostaglandins | 1 | 2018 | 18 | 0.150 |
Why?
|
| Influenza A Virus, H7N9 Subtype | 1 | 2018 | 7 | 0.150 |
Why?
|
| Stochastic Processes | 1 | 2018 | 28 | 0.150 |
Why?
|
| Agriculture | 1 | 2018 | 29 | 0.140 |
Why?
|
| Sperm Motility | 1 | 2018 | 49 | 0.140 |
Why?
|
| Betacoronavirus | 1 | 2020 | 183 | 0.140 |
Why?
|
| Genome-Wide Association Study | 1 | 2020 | 361 | 0.140 |
Why?
|
| Solutions | 2 | 2015 | 64 | 0.140 |
Why?
|
| Silent Mutation | 1 | 2018 | 5 | 0.140 |
Why?
|
| Calcium Channels | 1 | 2018 | 103 | 0.140 |
Why?
|
| Caenorhabditis elegans Proteins | 1 | 2023 | 430 | 0.140 |
Why?
|
| Pyrrolidines | 1 | 2017 | 14 | 0.140 |
Why?
|
| Interdisciplinary Communication | 1 | 2018 | 107 | 0.140 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2017 | 34 | 0.140 |
Why?
|
| Acute Disease | 9 | 2001 | 671 | 0.140 |
Why?
|
| Progesterone | 1 | 2018 | 163 | 0.140 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2017 | 60 | 0.140 |
Why?
|
| Genetic Fitness | 1 | 2018 | 36 | 0.140 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2018 | 184 | 0.130 |
Why?
|
| Drug Combinations | 1 | 2017 | 168 | 0.130 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 2018 | 462 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 8 | 4 | 1999 | 28 | 0.130 |
Why?
|
| Mutagenesis | 1 | 2017 | 133 | 0.130 |
Why?
|
| Nucleic Acid Conformation | 1 | 2018 | 238 | 0.130 |
Why?
|
| Surface Properties | 1 | 2018 | 281 | 0.130 |
Why?
|
| Zanamivir | 1 | 2016 | 5 | 0.130 |
Why?
|
| Blood Component Transfusion | 1 | 1996 | 11 | 0.130 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2016 | 58 | 0.130 |
Why?
|
| Granulocytes | 1 | 1996 | 73 | 0.120 |
Why?
|
| Catalysis | 2 | 2015 | 164 | 0.120 |
Why?
|
| High-Throughput Screening Assays | 2 | 2013 | 79 | 0.120 |
Why?
|
| Mutant Proteins | 2 | 2015 | 105 | 0.120 |
Why?
|
| Disulfides | 1 | 1996 | 66 | 0.120 |
Why?
|
| Spermatozoa | 1 | 2018 | 261 | 0.120 |
Why?
|
| Lipoproteins | 1 | 2016 | 84 | 0.120 |
Why?
|
| Bacterial Vaccines | 1 | 2016 | 81 | 0.120 |
Why?
|
| Caenorhabditis elegans | 1 | 2023 | 684 | 0.120 |
Why?
|
| Antigens, Surface | 1 | 2016 | 199 | 0.120 |
Why?
|
| Recombinant Proteins | 8 | 2017 | 705 | 0.120 |
Why?
|
| Borrelia burgdorferi | 1 | 2016 | 92 | 0.120 |
Why?
|
| Reassortant Viruses | 1 | 2015 | 10 | 0.110 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 1995 | 72 | 0.110 |
Why?
|
| Muramidase | 1 | 1995 | 47 | 0.110 |
Why?
|
| Small Molecule Libraries | 2 | 2013 | 59 | 0.110 |
Why?
|
| Lyme Disease | 1 | 2016 | 122 | 0.110 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2020 | 629 | 0.110 |
Why?
|
| Profilins | 1 | 2015 | 45 | 0.110 |
Why?
|
| Treatment Outcome | 8 | 2012 | 5696 | 0.110 |
Why?
|
| Myelodysplastic Syndromes | 3 | 2001 | 85 | 0.110 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 4 | 1998 | 49 | 0.110 |
Why?
|
| Membrane Potentials | 1 | 2014 | 141 | 0.110 |
Why?
|
| Stereoisomerism | 5 | 2019 | 70 | 0.110 |
Why?
|
| Plant Proteins | 1 | 1995 | 90 | 0.110 |
Why?
|
| Depsipeptides | 1 | 1994 | 5 | 0.110 |
Why?
|
| Surface-Active Agents | 1 | 1995 | 113 | 0.110 |
Why?
|
| Drug Administration Schedule | 5 | 2012 | 299 | 0.100 |
Why?
|
| Genetics, Population | 1 | 2014 | 44 | 0.100 |
Why?
|
| DNA Repair | 1 | 2015 | 250 | 0.100 |
Why?
|
| Electron Microscope Tomography | 2 | 2025 | 16 | 0.100 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 3 | 2012 | 86 | 0.100 |
Why?
|
| Microsomes | 1 | 2013 | 11 | 0.100 |
Why?
|
| Viral Structural Proteins | 1 | 2013 | 17 | 0.100 |
Why?
|
| Anemia, Refractory, with Excess of Blasts | 1 | 1993 | 2 | 0.100 |
Why?
|
| Madin Darby Canine Kidney Cells | 3 | 2019 | 22 | 0.100 |
Why?
|
| Azacitidine | 1 | 1993 | 15 | 0.100 |
Why?
|
| RNA, Viral | 3 | 2022 | 276 | 0.100 |
Why?
|
| Aged | 20 | 2001 | 14662 | 0.100 |
Why?
|
| Atazanavir Sulfate | 1 | 2013 | 2 | 0.100 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2007 | 329 | 0.100 |
Why?
|
| Binding, Competitive | 2 | 2010 | 98 | 0.100 |
Why?
|
| HIV | 1 | 2013 | 70 | 0.100 |
Why?
|
| Infusions, Intravenous | 4 | 2001 | 176 | 0.100 |
Why?
|
| Erythroid Precursor Cells | 1 | 1993 | 24 | 0.100 |
Why?
|
| Middle Aged | 21 | 2012 | 17921 | 0.100 |
Why?
|
| Gene Expression Regulation | 2 | 2023 | 1622 | 0.100 |
Why?
|
| Hematopoiesis | 1 | 1993 | 125 | 0.100 |
Why?
|
| Isoindoles | 1 | 2012 | 3 | 0.100 |
Why?
|
| 5-Methylcytosine | 1 | 2012 | 21 | 0.100 |
Why?
|
| Calmodulin | 1 | 2012 | 23 | 0.090 |
Why?
|
| Robotics | 1 | 2013 | 87 | 0.090 |
Why?
|
| Entropy | 1 | 2012 | 24 | 0.090 |
Why?
|
| Immunity, Innate | 2 | 2023 | 803 | 0.090 |
Why?
|
| Staurosporine | 1 | 2012 | 19 | 0.090 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2012 | 25 | 0.090 |
Why?
|
| Potassium Channels | 1 | 2012 | 58 | 0.090 |
Why?
|
| pol Gene Products, Human Immunodeficiency Virus | 1 | 2012 | 4 | 0.090 |
Why?
|
| Nucleoproteins | 2 | 2015 | 34 | 0.090 |
Why?
|
| Pyridines | 1 | 2013 | 114 | 0.090 |
Why?
|
| Male | 23 | 2021 | 30320 | 0.090 |
Why?
|
| Algorithms | 2 | 2015 | 1029 | 0.090 |
Why?
|
| Immunosuppressive Agents | 1 | 1994 | 381 | 0.090 |
Why?
|
| Female | 23 | 2024 | 33381 | 0.090 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 3 | 2000 | 70 | 0.090 |
Why?
|
| Cross-Linking Reagents | 2 | 2012 | 117 | 0.090 |
Why?
|
| Serine | 2 | 2008 | 91 | 0.090 |
Why?
|
| Clinical Trials as Topic | 3 | 2008 | 460 | 0.090 |
Why?
|
| Tandem Mass Spectrometry | 2 | 2012 | 147 | 0.090 |
Why?
|
| Genes, Viral | 1 | 2010 | 57 | 0.080 |
Why?
|
| Neurons | 2 | 2015 | 934 | 0.080 |
Why?
|
| Mass Spectrometry | 1 | 2012 | 303 | 0.080 |
Why?
|
| Neutralization Tests | 2 | 2021 | 127 | 0.080 |
Why?
|
| Trypsin | 1 | 1990 | 42 | 0.080 |
Why?
|
| Microbial Sensitivity Tests | 3 | 2019 | 209 | 0.080 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2015 | 508 | 0.080 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1990 | 112 | 0.080 |
Why?
|
| In Vitro Techniques | 4 | 2015 | 490 | 0.080 |
Why?
|
| Polymorphism, Genetic | 1 | 2010 | 191 | 0.080 |
Why?
|
| Swine | 2 | 2023 | 395 | 0.080 |
Why?
|
| Immunoglobulin G | 2 | 2022 | 463 | 0.080 |
Why?
|
| Virus Assembly | 3 | 2015 | 53 | 0.080 |
Why?
|
| Protein Interaction Domains and Motifs | 2 | 2020 | 86 | 0.070 |
Why?
|
| Survival Rate | 5 | 2012 | 859 | 0.070 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 1999 | 42 | 0.070 |
Why?
|
| Smoking | 1 | 1993 | 861 | 0.070 |
Why?
|
| Multiple Myeloma | 1 | 1994 | 347 | 0.070 |
Why?
|
| Colonic Neoplasms | 1 | 2010 | 221 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 21 | 2 | 1999 | 30 | 0.070 |
Why?
|
| Interferon Regulatory Factors | 1 | 2008 | 43 | 0.070 |
Why?
|
| Ritonavir | 1 | 2008 | 19 | 0.070 |
Why?
|
| p300-CBP Transcription Factors | 1 | 2008 | 10 | 0.070 |
Why?
|
| Adolescent | 12 | 2012 | 6305 | 0.070 |
Why?
|
| Rats | 4 | 2021 | 2005 | 0.070 |
Why?
|
| X-Ray Diffraction | 3 | 2015 | 62 | 0.070 |
Why?
|
| Saccharomyces cerevisiae | 2 | 2024 | 567 | 0.070 |
Why?
|
| Adult | 18 | 2012 | 17134 | 0.070 |
Why?
|
| Daunorubicin | 4 | 2000 | 7 | 0.070 |
Why?
|
| Viruses | 1 | 2009 | 81 | 0.070 |
Why?
|
| Drug Resistance, Multiple | 2 | 2012 | 32 | 0.070 |
Why?
|
| Interferon Regulatory Factor-3 | 1 | 2008 | 97 | 0.070 |
Why?
|
| Aged, 80 and over | 8 | 2001 | 5528 | 0.070 |
Why?
|
| Time Factors | 4 | 2001 | 3725 | 0.070 |
Why?
|
| CREB-Binding Protein | 1 | 2007 | 15 | 0.060 |
Why?
|
| Oxazoles | 1 | 2006 | 10 | 0.060 |
Why?
|
| Smad Proteins | 1 | 2007 | 23 | 0.060 |
Why?
|
| Interferon-alpha | 2 | 2000 | 103 | 0.060 |
Why?
|
| Double-Blind Method | 2 | 2001 | 744 | 0.060 |
Why?
|
| HCT116 Cells | 2 | 2020 | 52 | 0.060 |
Why?
|
| Rec A Recombinases | 1 | 2006 | 35 | 0.060 |
Why?
|
| Artificial Intelligence | 1 | 1990 | 197 | 0.060 |
Why?
|
| Predictive Value of Tests | 2 | 2007 | 1105 | 0.060 |
Why?
|
| Models, Statistical | 2 | 2006 | 309 | 0.060 |
Why?
|
| Camelids, New World | 1 | 2026 | 9 | 0.060 |
Why?
|
| Probability | 1 | 2006 | 169 | 0.060 |
Why?
|
| Transforming Growth Factor beta | 1 | 2007 | 174 | 0.060 |
Why?
|
| Sequence Analysis, RNA | 2 | 2019 | 180 | 0.060 |
Why?
|
| Elongin | 1 | 2025 | 1 | 0.060 |
Why?
|
| Manganese Compounds | 1 | 2005 | 8 | 0.060 |
Why?
|
| Cullin Proteins | 1 | 2025 | 9 | 0.060 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2010 | 310 | 0.060 |
Why?
|
| Geobacter | 1 | 2005 | 12 | 0.060 |
Why?
|
| Oxides | 1 | 2005 | 36 | 0.060 |
Why?
|
| Core Binding Factor beta Subunit | 1 | 2025 | 22 | 0.060 |
Why?
|
| Ferric Compounds | 1 | 2005 | 44 | 0.060 |
Why?
|
| Benzoxazoles | 1 | 2005 | 7 | 0.060 |
Why?
|
| Lysine | 1 | 2025 | 87 | 0.060 |
Why?
|
| Thiazoles | 1 | 2005 | 47 | 0.060 |
Why?
|
| Ubiquitination | 1 | 2025 | 113 | 0.060 |
Why?
|
| Moloney murine leukemia virus | 1 | 2024 | 17 | 0.060 |
Why?
|
| CCR5 Receptor Antagonists | 1 | 2024 | 16 | 0.060 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2024 | 32 | 0.050 |
Why?
|
| Administration, Oral | 2 | 2005 | 374 | 0.050 |
Why?
|
| Molecular Conformation | 3 | 2012 | 133 | 0.050 |
Why?
|
| Diffusion | 2 | 2005 | 82 | 0.050 |
Why?
|
| Cell Nucleus | 2 | 2005 | 634 | 0.050 |
Why?
|
| Cloning, Molecular | 2 | 2017 | 386 | 0.050 |
Why?
|
| Animals, Newborn | 1 | 2024 | 245 | 0.050 |
Why?
|
| Drug Delivery Systems | 2 | 2011 | 328 | 0.050 |
Why?
|
| Translocation, Genetic | 3 | 1999 | 71 | 0.050 |
Why?
|
| Cattle | 3 | 1995 | 316 | 0.050 |
Why?
|
| Energy Transfer | 1 | 2003 | 10 | 0.050 |
Why?
|
| Indazoles | 1 | 2023 | 17 | 0.050 |
Why?
|
| Enzyme Stability | 1 | 2003 | 47 | 0.050 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2025 | 224 | 0.050 |
Why?
|
| Triazines | 1 | 2023 | 21 | 0.050 |
Why?
|
| HIV Antibodies | 1 | 2024 | 148 | 0.050 |
Why?
|
| National Institutes of Health (U.S.) | 3 | 2021 | 119 | 0.050 |
Why?
|
| Motion | 1 | 2003 | 62 | 0.050 |
Why?
|
| Follow-Up Studies | 3 | 2001 | 2482 | 0.050 |
Why?
|
| Triazoles | 1 | 2023 | 62 | 0.050 |
Why?
|
| Triazenes | 1 | 2002 | 2 | 0.050 |
Why?
|
| Cathepsin L | 1 | 2022 | 22 | 0.050 |
Why?
|
| Immunophenotyping | 2 | 2001 | 197 | 0.050 |
Why?
|
| Gene Expression | 2 | 2017 | 851 | 0.050 |
Why?
|
| Adhesins, Bacterial | 1 | 2002 | 10 | 0.050 |
Why?
|
| Indinavir | 1 | 2002 | 2 | 0.050 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2023 | 108 | 0.050 |
Why?
|
| Cells, Cultured | 3 | 2015 | 2177 | 0.050 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2023 | 149 | 0.050 |
Why?
|
| Peptide Library | 1 | 2002 | 37 | 0.050 |
Why?
|
| Data Interpretation, Statistical | 1 | 2003 | 194 | 0.050 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2015 | 313 | 0.050 |
Why?
|
| Chlorambucil | 1 | 2001 | 3 | 0.040 |
Why?
|
| Vidarabine | 1 | 2001 | 7 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2002 | 142 | 0.040 |
Why?
|
| Actuarial Analysis | 1 | 2001 | 17 | 0.040 |
Why?
|
| Phylogeny | 2 | 2018 | 385 | 0.040 |
Why?
|
| Mitoxantrone | 1 | 2001 | 16 | 0.040 |
Why?
|
| Ontario | 1 | 2001 | 45 | 0.040 |
Why?
|
| Mammals | 1 | 2023 | 219 | 0.040 |
Why?
|
| Virus Integration | 1 | 2001 | 32 | 0.040 |
Why?
|
| Isoleucine | 1 | 2000 | 8 | 0.040 |
Why?
|
| Neoplasm, Residual | 1 | 2001 | 49 | 0.040 |
Why?
|
| T-Lymphoma Invasion and Metastasis-inducing Protein 1 | 1 | 2020 | 3 | 0.040 |
Why?
|
| Virulence | 1 | 2021 | 195 | 0.040 |
Why?
|
| Actins | 1 | 2002 | 261 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2001 | 249 | 0.040 |
Why?
|
| Neoplasm Proteins | 1 | 2002 | 283 | 0.040 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2002 | 268 | 0.040 |
Why?
|
| Glycine | 1 | 2000 | 50 | 0.040 |
Why?
|
| Antigens, Viral | 1 | 2021 | 137 | 0.040 |
Why?
|
| Pargyline | 1 | 2020 | 2 | 0.040 |
Why?
|
| Immunoglobulin A, Secretory | 1 | 2020 | 22 | 0.040 |
Why?
|
| Vero Cells | 1 | 2020 | 81 | 0.040 |
Why?
|
| Cadherins | 1 | 2020 | 82 | 0.040 |
Why?
|
| United States | 5 | 2021 | 7923 | 0.040 |
Why?
|
| Cross Reactions | 1 | 2020 | 134 | 0.040 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2020 | 49 | 0.040 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 2000 | 18 | 0.040 |
Why?
|
| Receptors, Cell Surface | 1 | 2002 | 430 | 0.040 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2000 | 23 | 0.040 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2021 | 625 | 0.040 |
Why?
|
| Bacteria | 1 | 2023 | 317 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 2 | 2001 | 726 | 0.040 |
Why?
|
| Tretinoin | 1 | 2000 | 48 | 0.040 |
Why?
|
| Escherichia coli Proteins | 1 | 2002 | 275 | 0.040 |
Why?
|
| Electrons | 1 | 1999 | 36 | 0.040 |
Why?
|
| Islets of Langerhans Transplantation | 1 | 2020 | 178 | 0.040 |
Why?
|
| Genetic Code | 1 | 2019 | 6 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 1 | 2022 | 685 | 0.040 |
Why?
|
| Reverse Genetics | 1 | 2019 | 10 | 0.040 |
Why?
|
| Mice, Inbred NOD | 1 | 2020 | 526 | 0.040 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2020 | 154 | 0.040 |
Why?
|
| Cell Movement | 1 | 2020 | 464 | 0.040 |
Why?
|
| Cell Line, Tumor | 2 | 2017 | 1494 | 0.040 |
Why?
|
| Autoimmunity | 1 | 2020 | 240 | 0.040 |
Why?
|
| Regression Analysis | 2 | 2000 | 498 | 0.040 |
Why?
|
| Vaccines, Synthetic | 1 | 2018 | 78 | 0.040 |
Why?
|
| RNA Folding | 1 | 2018 | 6 | 0.040 |
Why?
|
| Trisomy | 1 | 1998 | 21 | 0.030 |
Why?
|
| Nuclear Proteins | 1 | 2002 | 785 | 0.030 |
Why?
|
| Age Factors | 4 | 2012 | 1570 | 0.030 |
Why?
|
| Dendritic Cells | 1 | 2001 | 529 | 0.030 |
Why?
|
| Gene Rearrangement | 1 | 1998 | 41 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2020 | 532 | 0.030 |
Why?
|
| HIV Long Terminal Repeat | 2 | 2012 | 12 | 0.030 |
Why?
|
| Antibody Specificity | 1 | 2017 | 102 | 0.030 |
Why?
|
| Hodgkin Disease | 1 | 1998 | 54 | 0.030 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2017 | 35 | 0.030 |
Why?
|
| Genes, Tumor Suppressor | 1 | 1998 | 72 | 0.030 |
Why?
|
| Fluorescence Resonance Energy Transfer | 2 | 2009 | 81 | 0.030 |
Why?
|
| Endocrine Disruptors | 1 | 2018 | 79 | 0.030 |
Why?
|
| Oncogenes | 1 | 2017 | 70 | 0.030 |
Why?
|
| Pregnancy | 1 | 2024 | 2370 | 0.030 |
Why?
|
| Calcium Signaling | 1 | 2018 | 164 | 0.030 |
Why?
|
| Structural Homology, Protein | 1 | 2016 | 21 | 0.030 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 1997 | 33 | 0.030 |
Why?
|
| Blood Preservation | 1 | 1996 | 6 | 0.030 |
Why?
|
| Prognosis | 6 | 2000 | 1769 | 0.030 |
Why?
|
| Survivors | 1 | 1998 | 182 | 0.030 |
Why?
|
| Urea | 1 | 1996 | 39 | 0.030 |
Why?
|
| Clustered Regularly Interspaced Short Palindromic Repeats | 1 | 2017 | 101 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2010 | 458 | 0.030 |
Why?
|
| Chromosome Aberrations | 2 | 1993 | 67 | 0.030 |
Why?
|
| Thymidine Monophosphate | 1 | 1995 | 1 | 0.030 |
Why?
|
| Synchrotrons | 1 | 1995 | 6 | 0.030 |
Why?
|
| Deoxyuracil Nucleotides | 1 | 1995 | 3 | 0.030 |
Why?
|
| Adaptation, Psychological | 1 | 1998 | 270 | 0.030 |
Why?
|
| Chemistry, Physical | 1 | 1995 | 47 | 0.030 |
Why?
|
| Phosphates | 1 | 1996 | 93 | 0.030 |
Why?
|
| Pliability | 1 | 2015 | 6 | 0.030 |
Why?
|
| Phosphorylation | 2 | 2008 | 948 | 0.030 |
Why?
|
| Chemical Phenomena | 1 | 1995 | 96 | 0.030 |
Why?
|
| Pancreatin | 1 | 1995 | 2 | 0.030 |
Why?
|
| Trypsin Inhibitors | 1 | 1995 | 2 | 0.030 |
Why?
|
| Eukaryotic Cells | 1 | 1995 | 57 | 0.030 |
Why?
|
| alpha-Amylases | 1 | 1995 | 7 | 0.030 |
Why?
|
| Microsomes, Liver | 2 | 2005 | 21 | 0.030 |
Why?
|
| Orthomyxoviridae Infections | 1 | 2015 | 71 | 0.030 |
Why?
|
| Influenza A Virus, H1N2 Subtype | 1 | 2015 | 6 | 0.030 |
Why?
|
| Allosteric Site | 1 | 2015 | 31 | 0.030 |
Why?
|
| Phenylpyruvic Acids | 1 | 2015 | 2 | 0.030 |
Why?
|
| Hydroxylamines | 1 | 2015 | 7 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2020 | 2138 | 0.030 |
Why?
|
| Phenylpropionates | 1 | 2015 | 10 | 0.030 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 1 | 2015 | 28 | 0.030 |
Why?
|
| Chickens | 1 | 1995 | 94 | 0.030 |
Why?
|
| Limit of Detection | 1 | 2015 | 49 | 0.030 |
Why?
|
| Protein Interaction Mapping | 1 | 2015 | 68 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2015 | 123 | 0.030 |
Why?
|
| DNA Transposable Elements | 1 | 1995 | 140 | 0.030 |
Why?
|
| Karyotyping | 4 | 1997 | 47 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2015 | 197 | 0.030 |
Why?
|
| Lactococcus lactis | 1 | 1994 | 8 | 0.030 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2018 | 645 | 0.030 |
Why?
|
| Quality of Life | 2 | 2000 | 1257 | 0.030 |
Why?
|
| Genetic Drift | 1 | 2014 | 16 | 0.030 |
Why?
|
| Disease Progression | 2 | 2000 | 1174 | 0.030 |
Why?
|
| Genes, ras | 1 | 1994 | 27 | 0.030 |
Why?
|
| RNA, Transfer | 1 | 2015 | 92 | 0.030 |
Why?
|
| Leukemia, Myeloid, Chronic-Phase | 1 | 1993 | 6 | 0.030 |
Why?
|
| Viral Plaque Assay | 1 | 2013 | 16 | 0.030 |
Why?
|
| Blast Crisis | 1 | 1993 | 9 | 0.030 |
Why?
|
| Fluorescence Polarization | 1 | 2013 | 32 | 0.030 |
Why?
|
| Etoposide | 1 | 1993 | 33 | 0.030 |
Why?
|
| Cell Survival | 1 | 2015 | 582 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 1994 | 156 | 0.030 |
Why?
|
| Carboplatin | 1 | 1993 | 43 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2014 | 123 | 0.030 |
Why?
|
| Fluorescein | 1 | 2013 | 13 | 0.030 |
Why?
|
| Base Sequence | 2 | 2006 | 1335 | 0.030 |
Why?
|
| Models, Biological | 1 | 2018 | 1187 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2020 | 3449 | 0.020 |
Why?
|
| Vomiting | 1 | 1994 | 138 | 0.020 |
Why?
|
| KCNQ3 Potassium Channel | 1 | 2012 | 2 | 0.020 |
Why?
|
| Tetraethylammonium | 1 | 2012 | 9 | 0.020 |
Why?
|
| KCNQ2 Potassium Channel | 1 | 2012 | 4 | 0.020 |
Why?
|
| Survival Analysis | 3 | 1999 | 587 | 0.020 |
Why?
|
| Enzyme Induction | 1 | 2012 | 44 | 0.020 |
Why?
|
| Thymine | 1 | 2012 | 10 | 0.020 |
Why?
|
| Plasma | 1 | 2012 | 38 | 0.020 |
Why?
|
| Chemistry Techniques, Synthetic | 1 | 2012 | 11 | 0.020 |
Why?
|
| Erythrocyte Transfusion | 1 | 1993 | 76 | 0.020 |
Why?
|
| Xenopus laevis | 1 | 2012 | 68 | 0.020 |
Why?
|
| Ions | 1 | 2012 | 57 | 0.020 |
Why?
|
| Mental Disorders | 1 | 2000 | 794 | 0.020 |
Why?
|
| Nitrogen Isotopes | 1 | 2012 | 10 | 0.020 |
Why?
|
| Uracil | 1 | 2012 | 33 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2012 | 40 | 0.020 |
Why?
|
| Fluorescent Dyes | 1 | 2013 | 203 | 0.020 |
Why?
|
| HIV Integrase | 1 | 2012 | 7 | 0.020 |
Why?
|
| Ribonuclease H | 1 | 2012 | 18 | 0.020 |
Why?
|
| Blood Transfusion | 1 | 1993 | 162 | 0.020 |
Why?
|
| Thioguanine | 1 | 1991 | 1 | 0.020 |
Why?
|
| Vincristine | 1 | 1991 | 28 | 0.020 |
Why?
|
| Interferons | 1 | 2012 | 73 | 0.020 |
Why?
|
| Odds Ratio | 1 | 1993 | 759 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2012 | 183 | 0.020 |
Why?
|
| Plasmids | 1 | 2012 | 293 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 2012 | 296 | 0.020 |
Why?
|
| Prednisone | 1 | 1991 | 85 | 0.020 |
Why?
|
| Chromatography, Liquid | 1 | 2012 | 129 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2015 | 1000 | 0.020 |
Why?
|
| Antigens, CD34 | 2 | 2001 | 53 | 0.020 |
Why?
|
| Cytoplasm | 1 | 2012 | 279 | 0.020 |
Why?
|
| HIV Antigens | 1 | 2010 | 18 | 0.020 |
Why?
|
| Nervous System Diseases | 1 | 1992 | 107 | 0.020 |
Why?
|
| Anisotropy | 1 | 2010 | 63 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 1993 | 1131 | 0.020 |
Why?
|
| Risk Factors | 3 | 2000 | 5341 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2010 | 280 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2010 | 240 | 0.020 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2010 | 151 | 0.020 |
Why?
|
| Surveys and Questionnaires | 2 | 1998 | 2738 | 0.020 |
Why?
|
| Chitinases | 1 | 2009 | 10 | 0.020 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2010 | 146 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-abl | 1 | 2009 | 6 | 0.020 |
Why?
|
| Mitochondrial Proteins | 1 | 2010 | 106 | 0.020 |
Why?
|
| Movement | 1 | 2010 | 161 | 0.020 |
Why?
|
| Quantitative Structure-Activity Relationship | 1 | 2009 | 7 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2013 | 1682 | 0.020 |
Why?
|
| Health Planning Guidelines | 1 | 1988 | 32 | 0.020 |
Why?
|
| Health Planning | 1 | 1988 | 32 | 0.020 |
Why?
|
| Threonine | 1 | 2008 | 15 | 0.020 |
Why?
|
| Cytomegalovirus | 1 | 2009 | 94 | 0.020 |
Why?
|
| Lopinavir | 1 | 2007 | 5 | 0.020 |
Why?
|
| Pyrimidinones | 1 | 2007 | 17 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2009 | 467 | 0.020 |
Why?
|
| California | 1 | 2006 | 175 | 0.020 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2007 | 94 | 0.020 |
Why?
|
| Deltaproteobacteria | 1 | 2005 | 3 | 0.010 |
Why?
|
| Logistic Models | 2 | 2000 | 1270 | 0.010 |
Why?
|
| Molecular Weight | 1 | 2005 | 190 | 0.010 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2005 | 47 | 0.010 |
Why?
|
| Apoptosis | 1 | 2010 | 1095 | 0.010 |
Why?
|
| Genome, Bacterial | 1 | 2005 | 68 | 0.010 |
Why?
|
| DNA Primers | 1 | 2005 | 295 | 0.010 |
Why?
|
| Drug Stability | 1 | 2005 | 144 | 0.010 |
Why?
|
| Adenosine Triphosphatases | 1 | 2006 | 256 | 0.010 |
Why?
|
| Rats, Wistar | 1 | 2005 | 187 | 0.010 |
Why?
|
| Biological Transport | 1 | 2005 | 291 | 0.010 |
Why?
|
| Protein Transport | 1 | 2005 | 405 | 0.010 |
Why?
|
| Biological Availability | 1 | 2005 | 204 | 0.010 |
Why?
|
| Gene Deletion | 1 | 2005 | 312 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 2005 | 402 | 0.010 |
Why?
|
| Information Storage and Retrieval | 1 | 2003 | 60 | 0.010 |
Why?
|
| Dithiothreitol | 1 | 2002 | 18 | 0.010 |
Why?
|
| Glutathione Transferase | 1 | 2002 | 41 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2002 | 32 | 0.010 |
Why?
|
| Cohort Studies | 2 | 2000 | 2605 | 0.010 |
Why?
|
| Glutathione | 1 | 2002 | 56 | 0.010 |
Why?
|
| Two-Hybrid System Techniques | 1 | 2002 | 67 | 0.010 |
Why?
|
| Neoplasm Staging | 2 | 1998 | 529 | 0.010 |
Why?
|
| Cysteine | 1 | 2002 | 108 | 0.010 |
Why?
|
| Young Adult | 1 | 2012 | 4781 | 0.010 |
Why?
|
| Sialic Acid Binding Ig-like Lectin 3 | 1 | 2001 | 1 | 0.010 |
Why?
|
| CD2 Antigens | 1 | 2001 | 3 | 0.010 |
Why?
|
| CD13 Antigens | 1 | 2001 | 6 | 0.010 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2001 | 20 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2003 | 417 | 0.010 |
Why?
|
| Prospective Studies | 2 | 1999 | 3318 | 0.010 |
Why?
|
| CD56 Antigen | 1 | 2001 | 17 | 0.010 |
Why?
|
| Antigens, CD19 | 1 | 2001 | 25 | 0.010 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2001 | 28 | 0.010 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2001 | 144 | 0.010 |
Why?
|
| Reference Standards | 1 | 2000 | 74 | 0.010 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2001 | 114 | 0.010 |
Why?
|
| Terminology as Topic | 1 | 2001 | 142 | 0.010 |
Why?
|
| Bone Marrow | 2 | 1992 | 175 | 0.010 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2000 | 26 | 0.010 |
Why?
|
| Databases, Factual | 1 | 2003 | 856 | 0.010 |
Why?
|
| DNA, Viral | 1 | 2001 | 234 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2001 | 348 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2001 | 320 | 0.010 |
Why?
|
| Pericardial Effusion | 1 | 2000 | 21 | 0.010 |
Why?
|
| Pleural Effusion | 1 | 2000 | 40 | 0.010 |
Why?
|
| Fever | 1 | 2000 | 66 | 0.010 |
Why?
|
| Syndrome | 1 | 2000 | 180 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2001 | 519 | 0.010 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2001 | 285 | 0.010 |
Why?
|
| Global Health | 1 | 2000 | 183 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2001 | 668 | 0.010 |
Why?
|
| Recurrence | 1 | 2001 | 652 | 0.010 |
Why?
|
| Child | 2 | 2000 | 4583 | 0.010 |
Why?
|
| Monocytes | 1 | 2001 | 357 | 0.010 |
Why?
|
| Prevalence | 1 | 2003 | 1407 | 0.010 |
Why?
|
| Weight Gain | 1 | 2000 | 168 | 0.010 |
Why?
|
| Dexamethasone | 1 | 2000 | 207 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2001 | 1164 | 0.010 |
Why?
|
| Glucocorticoids | 1 | 2000 | 189 | 0.010 |
Why?
|
| Blotting, Southern | 1 | 1998 | 55 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2000 | 930 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 1998 | 412 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2001 | 884 | 0.010 |
Why?
|
| Meningeal Neoplasms | 1 | 1997 | 60 | 0.010 |
Why?
|
| Incidence | 1 | 2000 | 1385 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2001 | 1365 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 1998 | 788 | 0.010 |
Why?
|
| Sex Factors | 1 | 1998 | 980 | 0.010 |
Why?
|
| Infant | 1 | 2000 | 1664 | 0.010 |
Why?
|
| Lung | 1 | 2000 | 964 | 0.010 |
Why?
|
| Osmolar Concentration | 1 | 1994 | 89 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2000 | 2019 | 0.010 |
Why?
|
| Registries | 1 | 1998 | 885 | 0.010 |
Why?
|
| Stress, Psychological | 1 | 1998 | 479 | 0.010 |
Why?
|
| Nucleic Acids | 1 | 1994 | 60 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 1998 | 1561 | 0.010 |
Why?
|
| Chromosome Banding | 1 | 1992 | 13 | 0.010 |
Why?
|
| Aspartate Aminotransferases | 1 | 1992 | 35 | 0.010 |
Why?
|
| Alkaline Phosphatase | 1 | 1992 | 47 | 0.010 |
Why?
|
| Creatinine | 1 | 1992 | 133 | 0.010 |
Why?
|
| Blood Cell Count | 1 | 1990 | 33 | 0.010 |
Why?
|
| Leukemia, B-Cell | 1 | 1988 | 6 | 0.000 |
Why?
|
| Drug Evaluation | 1 | 1988 | 19 | 0.000 |
Why?
|
| International Cooperation | 1 | 1989 | 90 | 0.000 |
Why?
|
| Eligibility Determination | 1 | 1988 | 36 | 0.000 |
Why?
|
| Biopsy | 1 | 1990 | 449 | 0.000 |
Why?
|
| Breast Neoplasms | 1 | 1997 | 1213 | 0.000 |
Why?
|